

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/S9299C8883E8EN.html>

Date: August 2022

Pages: 69

Price: US\$ 3,500.00 (Single User License)

ID: S9299C8883E8EN

Abstracts

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Superoxide Dismutase [Cu-Zn] - Drugs In Development, 2022'; Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide (O₂⁻) radical into either ordinary molecular oxygen (O₂) or hydrogen peroxide (H₂O₂) which prevents damage to tissues. Superoxide dismutase is used for treating pain and swelling (inflammation) caused by osteoarthritis, sports injuries, and rheumatoid arthritis, a kidney condition called interstitial cystitis, gout, poisoning caused by a weed-killer called paraquat, cancer, and lung problems in newborns.

The report 'Superoxide Dismutase [Cu-Zn] - Drugs In Development, 2022' outlays

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15....

comprehensive information on the Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal and Genetic Disorders which include indications Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Parkinson's Disease, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Wilson Disease.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)

The report reviews Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Superoxide

Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Overview

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Companies Involved in Therapeutics Development

AL-S Pharma AG

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Apic Bio Inc

Avrion Therapeutics AG

Biogen Inc

Collaborative Medicinal Development LLC

Novartis Gene Therapies

ProMIS Neurosciences Inc

ResQ Biotech

Thera Neuropharma Inc

Voyager Therapeutics Inc

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Drug Profiles

ALN-SOD - Drug Profile

Product Description

Mechanism Of Action

History of Events

AP-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

APB-102 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AVR-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AVXS-301 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cu(II)ATSM - Drug Profile

Product Description

Mechanism Of Action

History of Events

NU-9 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Peptides to Inhibit Superoxide Dismutase (SOD1) for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

SOD1 - Drug Profile

Product Description

Mechanism Of Action

TDI-186 - Drug Profile

Product Description

Mechanism Of Action

THN-1 - Drug Profile

Product Description

Mechanism Of Action

History of Events

tiomolibdate choline - Drug Profile

Product Description

Mechanism Of Action

History of Events

tofersen sodium - Drug Profile

Product Description

Mechanism Of Action

History of Events

VYSOD-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VYSOD-102 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Dormant Products

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Product Development Milestones

Featured News & Press Releases

Jul 27, 2022: FDA grants priority review for Biogen's tofersen to treat ALS

Jul 26, 2022: Ionis announces that FDA accepts New Drug Application and grants priority review of tofersen for a rare, genetic form of ALS

Jun 23, 2022: ALXN1840 shows rapid and sustained improvement in copper mobilization from tissues, potentially closing treatment gaps for Wilson Disease community

Jun 03, 2022: Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients

Jun 03, 2022: New 12-month tofersen data presented at ENCALS meeting show clinically meaningful benefit in people with SOD1-ALS

Nov 18, 2021: Neurimmune and TVM Capital Life Science announce the initiation of AL-S Pharma's phase 2 Study of AP-101 for the treatment of ALS

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15....

Oct 18, 2021: Biogen's tofersen fails to meet primary goal in Phase III ALS trial

Oct 17, 2021: Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS

Oct 14, 2021: Topline results from Tofersen phase 3 study and its open label extension in SOD1-ALS to be presented at the American Neurological Association Annual Meeting

Aug 27, 2021: Alexion's drug meets primary goal in Phase III Wilson disease trial

Jul 28, 2021: Apic Bio receives FDA fast track designation for APB-102 for the treatment of patients with SOD1 ALS

Apr 21, 2021: Apic Bio announces FDA clearance of IND application for lead gene therapy candidate APB-102 for the treatment of SOD1 ALS

Feb 23, 2021: ALS neuron damage reversed with new compound

Jul 23, 2020: Investigational drug for genetic form of ALS showing early promise, trial indicates

Jul 13, 2020: New treatment for motor neurone disease shows promise in early trials

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AL-S Pharma AG, 2022
Pipeline by Alexion Pharmaceuticals Inc, 2022
Pipeline by Alnylam Pharmaceuticals Inc, 2022
Pipeline by Apic Bio Inc, 2022
Pipeline by Avrion Therapeutics AG, 2022
Pipeline by Biogen Inc, 2022
Pipeline by Collaborative Medicinal Development LLC, 2022
Pipeline by Novartis Gene Therapies, 2022
Pipeline by ProMIS Neurosciences Inc, 2022
Pipeline by ResQ Biotech, 2022
Pipeline by Thera Neuropharma Inc, 2022
Pipeline by Voyager Therapeutics Inc, 2022
Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/S9299C8883E8EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S9299C8883E8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970